Announcements
- Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
- Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
- Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
- Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
- Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
- Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
- Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
- Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
- Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
- Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.45 |
---|---|
High | 7.45 |
Low | 7.45 |
Bid | 7.16 |
Offer | 7.73 |
Previous close | 7.09 |
Average volume | 228.57 |
---|---|
Shares outstanding | 42.42m |
Free float | 18.75m |
P/E (TTM) | -- |
Market cap | 339.36m USD |
EPS (TTM) | -1.46 USD |
Data delayed at least 15 minutes, as of May 13 2024 08:10 BST.
More ▼